These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 36712686)

  • 1. Adherence and treatment patterns of disease-specific drugs among patients with pulmonary arterial hypertension: A nationwide, new-user cohort study.
    Tsai CY; Shen CW; Lai HL; Chen CY
    Front Pharmacol; 2022; 13():1030693. PubMed ID: 36712686
    [No Abstract]   [Full Text] [Related]  

  • 2. Medication adherence, hospitalization, and healthcare resource utilization and costs in patients with pulmonary arterial hypertension treated with endothelin receptor antagonists or phosphodiesterase type-5 inhibitors.
    Frantz RP; Hill JW; Lickert CA; Wade RL; Cole MR; Tsang Y; Drake W
    Pulm Circ; 2020; 10(1):2045894019880086. PubMed ID: 32274010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension Patients in the United States.
    Burger CD; Ozbay AB; Lazarus HM; Riehle E; Montejano LB; Lenhart G; White RJ
    J Manag Care Spec Pharm; 2018 Aug; 24(8):834-842. PubMed ID: 29436260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment patterns, healthcare resource utilization, and healthcare costs among patients with pulmonary arterial hypertension in a real-world US database.
    Studer S; Hull M; Pruett J; Koep E; Tsang Y; Drake W
    Pulm Circ; 2019; 9(1):2045894018816294. PubMed ID: 30421652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective Database Analysis of Treatment Patterns Among Patients with Pulmonary Arterial Hypertension.
    Studer S; Hull M; Pruett J; Elliott C; Tsang Y; Drake W
    Pulm Ther; 2020 Jun; 6(1):79-92. PubMed ID: 32048240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing adherence and persistence across 6 chronic medication classes.
    Yeaw J; Benner JS; Walt JG; Sian S; Smith DB
    J Manag Care Pharm; 2009; 15(9):728-40. PubMed ID: 19954264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with adherence to phosphodiesterase type 5 inhibitors for the treatment of pulmonary arterial hypertension.
    Waxman A; Chen SY; Boulanger L; Watson JA; Golden G
    J Med Econ; 2013; 16(2):298-306. PubMed ID: 23216015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of endothelin receptor antagonists, alone and in combination therapy, in the pulmonary arterial hypertension-connective tissue disease subtype: A systematic review and meta-analysis.
    Shivakumar S; Thynne TR; Mohammadi L; Burdeniuk C; Mangoni AA
    Int J Rheum Dis; 2020 Oct; 23(10):1276-1287. PubMed ID: 32691518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Patterns Associated with ACR-Recommended Medications in the Management of Fibromyalgia in the United States.
    Liu Y; Qian C; Yang M
    J Manag Care Spec Pharm; 2016 Mar; 22(3):263-71. PubMed ID: 27003556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Sildenafil in Pulmonary Arterial Hypertension: Findings from a U.S. Healthcare Claims Database.
    Berger A; Edelsberg J; Teal S; Mychaskiw MA; Oster G
    J Health Econ Outcomes Res; 2014; 1(3):254-265. PubMed ID: 34430662
    [No Abstract]   [Full Text] [Related]  

  • 11. Using Real World Evidence to Describe Pulmonary Arterial Hypertension Treatment Patterns, Healthcare Resource Utilization, and Costs Associated with PDE-5 Inhibitor Monotherapy.
    Ruiz G; Yeaw J; Lickert CA; De AP; Wade RL; Pruett J; Drake W
    J Health Econ Outcomes Res; 2018; 5(2):206-219. PubMed ID: 35620777
    [No Abstract]   [Full Text] [Related]  

  • 12. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.
    Hoeper MM; Al-Hiti H; Benza RL; Chang SA; Corris PA; Gibbs JSR; Grünig E; Jansa P; Klinger JR; Langleben D; McLaughlin VV; Meyer GMB; Ota-Arakaki J; Peacock AJ; Pulido T; Rosenkranz S; Vizza CD; Vonk-Noordegraaf A; White RJ; Chang M; Kleinjung F; Meier C; Paraschin K; Ghofrani HA; Simonneau G;
    Lancet Respir Med; 2021 Jun; 9(6):573-584. PubMed ID: 33773120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the combination of endothelin receptor antagonists (ERA) and phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension (PAH) in pathologic human pulmonary arteries in an ex-vivo organ bath model.
    Englert L; Stadlbauer C; Spaeth M; Hofmann HS; Schneider C; Hatz RA; Preissler G; Michel S; Golovchenko S; Ried M; Hoenicka M
    Pulm Pharmacol Ther; 2021 Feb; 66():101985. PubMed ID: 33359621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of adults with Eisenmenger syndrome treated with drugs specific to pulmonary arterial hypertension: A French multicentre study.
    Hascoet S; Fournier E; Jaïs X; Le Gloan L; Dauphin C; Houeijeh A; Godart F; Iriart X; Richard A; Radojevic J; Amedro P; Bosser G; Souletie N; Bernard Y; Moceri P; Bouvaist H; Mauran P; Barre E; Basquin A; Karsenty C; Bonnet D; Iserin L; Sitbon O; Petit J; Fadel E; Humbert M; Ladouceur M
    Arch Cardiovasc Dis; 2017 May; 110(5):303-316. PubMed ID: 28286190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment.
    Grünig E; Ohnesorge J; Benjamin N; Burhenne J; Enderle Y; Egenlauf B; Fischer C; Harutyunova S; Huppertz A; Klose H; Haefeli WE
    Respiration; 2017; 94(1):26-37. PubMed ID: 28494463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High rates of medication adherence in patients with pulmonary arterial hypertension: An integrated specialty pharmacy approach.
    Shah NB; Mitchell RE; Proctor ST; Choi L; DeClercq J; Jolly JA; Hemnes AR; Zuckerman AD
    PLoS One; 2019; 14(6):e0217798. PubMed ID: 31170217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longterm Efficacy and Safety of Monotherapy versus Combination Therapy in Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Retrospective RESCLE Registry Study.
    Pestaña-Fernández M; Rubio-Rivas M; Tolosa-Vilella C; Guillén-Del-Castillo A; Freire M; Vargas-Hitos JA; Todolí-Parra JA; Rodríguez-Carballeira M; Marín-Ballvé A; Espinosa G; Colunga-Argüelles D; Ortego-Centeno N; Trapiella-Martínez L; Carbonell-Muñoz C; Pla-Salas X; Perales-Fraile I; Corbella X; Fonollosa-Pla V; Simeón-Aznar CP;
    J Rheumatol; 2020 Jan; 47(1):89-98. PubMed ID: 30770503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in the Characteristics and Initial Treatments of Pulmonary Hypertension Between 2008 and 2020 in Japan.
    Tamura Y; Kumamaru H; Inami T; Matsubara H; Hirata KI; Tsujino I; Suda R; Miyata H; Nishimura S; Sigel B; Takano M; Tatsumi K;
    JACC Asia; 2022 Jun; 2(3):273-284. PubMed ID: 36338395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Pharmacist Telephone Intervention to Identify Adherence Barriers and Improve Adherence Among Nonadherent Patients with Comorbid Hypertension and Diabetes in a Medicare Advantage Plan.
    Abughosh SM; Wang X; Serna O; Henges C; Masilamani S; Essien EJ; Chung N; Fleming M
    J Manag Care Spec Pharm; 2016 Jan; 22(1):63-73. PubMed ID: 27015053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment patterns and healthcare system burden of managed care patients with suspected pulmonary arterial hypertension in the United States.
    Copher R; Cerulli A; Watkins A; Laura Monsalvo M
    J Med Econ; 2012; 15(5):947-55. PubMed ID: 22554140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.